sotalol | Sotagexal tablets 80 mg, 20 pcs.
Special Price
$14.70
Regular Price
$22.00
In stock
SKU
BID475008
Latin name
SotaHEXAL
SotaHEXAL
Latin name
SotaHEXAL
Release form
tablets
packaging 20 pcs
Pharmacological action
SotaHEXAL has an antiarrhythmic effect. Blocks beta1- and beta2-adrenergic receptors. Reduces heart rate, myocardial contractility, slows AV conduction. SOTAHEXAL increases the tone of the smooth muscles of the bronchi.
Indications
Supraventricular tachyarrhythmia: nodal tachycardia, tachycardia with WPW syndrome, paroxysmal atrial fibrillation, ventricular tachycardia, ventricular extrasystole.
Contraindications
Hypersensitivity (including sulfanilamides), chronic heart failure, stage IIb-III, shock, AV block II-III degree, sinoatrial block, sinus node weakness syndrome, bradycardia, prolongation of the QT interval, hypokalemia, hypokalemia severe peripheral circulatory disorders, obstructive airways diseases (including bronchial asthma), metabolic acidosis, laryngeal edema, myasthenia gravis, severe allergic rhinitis.
Use during pregnancy and lactation
In the first trimester of pregnancy, it is possible for strict medical reasons, with a thorough analysis of all risk factors. At the time of treatment should stop breastfeeding.
Composition
1 tablet contains:
Active ingredient: sotalol hydrochloride 80 mg
Excipients: corn starch lactose hydroxypropyl cellulose sodium glycolate glycolate magnesium dioxide stearate
Dosage and administration of
SOTAHEXAL is taken orally, before meals, without chewing, with a sufficient amount of liquid, 80-120 mg / day. in 2-3 doses. With insufficient effectiveness - up to 160-240-320 mg / day. in 2-3 doses. In severe arrhythmias, up to 480 mg / day. in 2-3 doses. The dose increase should be carried out with an interval of 2-3 days.
Side effects
From the nervous system and sensory organs: dizziness, headache, tiredness, sleep disturbance, confusion, paresthesia, depression. Inflammation of the cornea and conjunctiva (should be considered when wearing contact lenses), visual impairment (extremely rare), decreased tearing.
From the cardiovascular system and blood (hematopoiesis, hemostasis): heart failure, bradycardia, AV block, angina pectoris (in rare cases), hypotension.
From the respiratory system: bronchospasm.
From the digestive tract: nausea, diarrhea, constipation, dry mouth.
From the side of metabolism: hypoglycemia (more often in patients with diabetes mellitus or with strict diet).
From the genitourinary system: decreased potency.
From the musculoskeletal system: a feeling of coldness in the limbs, muscle weakness or cramps.
On the part of the skin: skin rash, itching (rarely) redness, psoriasiform dermatosis, alopecia.
Drug Interaction
At simultaneous appointment of Enam with NSAIDs it is possible to reduce the hypotensive effect of enalapril
with potassium diuretics (spironolactone, triamterene, amiloride) - the development of hyperkalium
Ethanol enhances the antihypertensive effect of the drug.
When used with antipyretic and analgesic drugs, Enam's effectiveness may be reduced. Enalapril weakens the action of theophylline-containing drugs. Cimetidine prolongs the action of enalapril. amiodarone) may cause marked QT lengthening. Drugs that increase the duration of the QT interval should be used with caution with drugs that prolong the QT interval, such as class I antiarrhythmic agents, phenothiazines, tricyclic antidepressants, terfenadine and astemizole, as well as some quinoladone antibiotics.
A decrease in blood pressure may occur with concomitant administration of nifedipine and other 1,4-dihydropyridine derivatives.
Concurrent administration of norepinephrine or MAO inhibitors, as well as abrupt withdrawal of clonidine, can cause hypertension. In this case, the withdrawal of clonidine should be carried out gradually and only a few days after the end of Sotageksal.
Tricyclic antidepressants, barbiturates, phenothiazines, opioid and antihypertensive agents, can lead to an increase in hypoglycemia and the manifestation of its symptoms (excessive sweating, increased heart rate, tremor). In diabetes mellitus, dosage adjustment of insulin and / or hypoglycemic agents is required.
Potassium eliminating diuretics (eg, furosemide, hydrochlorothiazide) can provoke the occurrence of arrhythmia caused by hypokalemia.
Higher doses of beta-adrenomimetics such as salbutamol, terbutaline and isoprenaline may be required when co-administered with Sotageksal.
Overdose
Symptoms: decreased blood pressure, bradycardia, bronchospasm, hypoglycemia, loss of consciousness, generalized seizures, ventricular tachycardia in severe cases - symptoms of cardiogenic shock, asystole.
Treatment: gastric lavage, hemodialysis, appointment of activated charcoal. Symptomatic therapy: atropine - 1-2 times in / in jet glucagon - first in the form of a short in / in infusion at a dose of 0.2 mg / kg body weight, then - at a dose of 0.5 mg / kg body weight / infusion for 12 hours
Storage conditions
In the dark place at a temperature of no higher than 25 РC.
Expiration
5 Chron
Day tvuyuschee substances
sotalol
dosage form
dosage form
tablets
Sandoz, Switzerland
SotaHEXAL
Release form
tablets
packaging 20 pcs
Pharmacological action
SotaHEXAL has an antiarrhythmic effect. Blocks beta1- and beta2-adrenergic receptors. Reduces heart rate, myocardial contractility, slows AV conduction. SOTAHEXAL increases the tone of the smooth muscles of the bronchi.
Indications
Supraventricular tachyarrhythmia: nodal tachycardia, tachycardia with WPW syndrome, paroxysmal atrial fibrillation, ventricular tachycardia, ventricular extrasystole.
Contraindications
Hypersensitivity (including sulfanilamides), chronic heart failure, stage IIb-III, shock, AV block II-III degree, sinoatrial block, sinus node weakness syndrome, bradycardia, prolongation of the QT interval, hypokalemia, hypokalemia severe peripheral circulatory disorders, obstructive airways diseases (including bronchial asthma), metabolic acidosis, laryngeal edema, myasthenia gravis, severe allergic rhinitis.
Use during pregnancy and lactation
In the first trimester of pregnancy, it is possible for strict medical reasons, with a thorough analysis of all risk factors. At the time of treatment should stop breastfeeding.
Composition
1 tablet contains:
Active ingredient: sotalol hydrochloride 80 mg
Excipients: corn starch lactose hydroxypropyl cellulose sodium glycolate glycolate magnesium dioxide stearate
Dosage and administration of
SOTAHEXAL is taken orally, before meals, without chewing, with a sufficient amount of liquid, 80-120 mg / day. in 2-3 doses. With insufficient effectiveness - up to 160-240-320 mg / day. in 2-3 doses. In severe arrhythmias, up to 480 mg / day. in 2-3 doses. The dose increase should be carried out with an interval of 2-3 days.
Side effects
From the nervous system and sensory organs: dizziness, headache, tiredness, sleep disturbance, confusion, paresthesia, depression. Inflammation of the cornea and conjunctiva (should be considered when wearing contact lenses), visual impairment (extremely rare), decreased tearing.
From the cardiovascular system and blood (hematopoiesis, hemostasis): heart failure, bradycardia, AV block, angina pectoris (in rare cases), hypotension.
From the respiratory system: bronchospasm.
From the digestive tract: nausea, diarrhea, constipation, dry mouth.
From the side of metabolism: hypoglycemia (more often in patients with diabetes mellitus or with strict diet).
From the genitourinary system: decreased potency.
From the musculoskeletal system: a feeling of coldness in the limbs, muscle weakness or cramps.
On the part of the skin: skin rash, itching (rarely) redness, psoriasiform dermatosis, alopecia.
Drug Interaction
At simultaneous appointment of Enam with NSAIDs it is possible to reduce the hypotensive effect of enalapril
with potassium diuretics (spironolactone, triamterene, amiloride) - the development of hyperkalium
Ethanol enhances the antihypertensive effect of the drug.
When used with antipyretic and analgesic drugs, Enam's effectiveness may be reduced. Enalapril weakens the action of theophylline-containing drugs. Cimetidine prolongs the action of enalapril. amiodarone) may cause marked QT lengthening. Drugs that increase the duration of the QT interval should be used with caution with drugs that prolong the QT interval, such as class I antiarrhythmic agents, phenothiazines, tricyclic antidepressants, terfenadine and astemizole, as well as some quinoladone antibiotics.
A decrease in blood pressure may occur with concomitant administration of nifedipine and other 1,4-dihydropyridine derivatives.
Concurrent administration of norepinephrine or MAO inhibitors, as well as abrupt withdrawal of clonidine, can cause hypertension. In this case, the withdrawal of clonidine should be carried out gradually and only a few days after the end of Sotageksal.
Tricyclic antidepressants, barbiturates, phenothiazines, opioid and antihypertensive agents, can lead to an increase in hypoglycemia and the manifestation of its symptoms (excessive sweating, increased heart rate, tremor). In diabetes mellitus, dosage adjustment of insulin and / or hypoglycemic agents is required.
Potassium eliminating diuretics (eg, furosemide, hydrochlorothiazide) can provoke the occurrence of arrhythmia caused by hypokalemia.
Higher doses of beta-adrenomimetics such as salbutamol, terbutaline and isoprenaline may be required when co-administered with Sotageksal.
Overdose
Symptoms: decreased blood pressure, bradycardia, bronchospasm, hypoglycemia, loss of consciousness, generalized seizures, ventricular tachycardia in severe cases - symptoms of cardiogenic shock, asystole.
Treatment: gastric lavage, hemodialysis, appointment of activated charcoal. Symptomatic therapy: atropine - 1-2 times in / in jet glucagon - first in the form of a short in / in infusion at a dose of 0.2 mg / kg body weight, then - at a dose of 0.5 mg / kg body weight / infusion for 12 hours
Storage conditions
In the dark place at a temperature of no higher than 25 РC.
Expiration
5 Chron
Day tvuyuschee substances
sotalol
dosage form
dosage form
tablets
Sandoz, Switzerland
Write Your Own Review